Original Article

You have full text access to this OnlineOpen article

Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

  1. Farhad Ravandi MD†,*,
  2. Jean-Pierre Issa MD,
  3. Guillermo Garcia-Manero MD,
  4. Susan O'Brien MD,
  5. Sherry Pierce BSN,
  6. Jianqin Shan PhD,
  7. Gautam Borthakur MD,
  8. Srdan Verstovsek MD,
  9. Stefan Faderl MD,
  10. Jorge Cortes MD,
  11. Hagop Kantarjian MD

Article first published online: 30 SEP 2009

DOI: 10.1002/cncr.24661

Issue

Cancer

Cancer

Volume 115, Issue 24, pages 5746–5751, 15 December 2009

Additional Information

How to Cite

Ravandi, F., Issa, J.-P., Garcia-Manero, G., O'Brien, S., Pierce, S., Shan, J., Borthakur, G., Verstovsek, S., Faderl, S., Cortes, J. and Kantarjian, H. (2009), Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer, 115: 5746–5751. doi: 10.1002/cncr.24661

Author Information

  1. Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 563-5774

*Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030

Publication History

  1. Issue published online: 2 DEC 2009
  2. Article first published online: 30 SEP 2009
  3. Manuscript Accepted: 12 MAR 2009
  4. Manuscript Revised: 5 MAR 2009
  5. Manuscript Received: 15 JAN 2009

Funded by

  • National Cancer Institute. Grant Number: 5P01 CA108631

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (154K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Michael A. McDevitt, Clinical Applications of Epigenetic Markers and Epigenetic Profiling in Myeloid Malignancies, Seminars in Oncology, 2012, 39, 1, 109

    CrossRef

  2. 2
    Peter W Marks, Decitabine for acute myeloid leukemia, Expert Review of Anticancer Therapy, 2012, 12, 3, 299

    CrossRef

  3. 3
    M. A. Sekeres, H. Gundacker, J. Lancet, A. Advani, S. Petersdorf, J. Liesveld, D. Mulford, T. Norwood, C. L. Willman, F. R. Appelbaum, A. F. List, A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605, Blood, 2011, 118, 3, 523

    CrossRef

  4. 4
    Sagun D Goyal, Amanda Cashen, Decitabine for the treatment of older patients with myelodysplastic syndrome and acute myelogenous leukemia, Aging Health, 2011, 7, 3, 363

    CrossRef

  5. 5
    Till Schoofs, Carsten Müller-Tidow, DNA methylation as a pathogenic event and as a therapeutic target in AML, Cancer Treatment Reviews, 2011, 37, S13

    CrossRef

  6. 6
    Felicetto Ferrara, Pellegrino Musto, Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly, Cancer, 2011, 117, 17
    Direct Link:
  7. 7
    Lagadinou D. Eleni, Zoumbos C. Nicholas, Spyridonidis Alexandros, Challenges in Treating Older Patients with Acute Myeloid Leukemia, Journal of Oncology, 2010, 2010, 1

    CrossRef

  8. 8
    Michael Rytting, Farhad Ravandi, Elihu Estey, Jorge Cortes, Stefan Faderl, Guillermo Garcia-Manero, Sima Jeha, Souzanne Ouzounian, Sherry Pierce, Hagop Kantarjian, Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia, Cancer, 2010, 116, 22
    Direct Link:
  9. 9
    Ellen K. Ritchie, Gail J. Roboz, Levels of Care: Defining Best Supportive Care in Elderly Patients with Acute Myeloid Leukemia, Current Hematologic Malignancy Reports, 2010, 5, 2, 95

    CrossRef

  10. 10
    R. Itzykson, S. Thepot, B. Quesnel, F. Dreyfus, O. Beyne-Rauzy, P. Turlure, N. Vey, C. Recher, C. Dartigeas, L. Legros, J. Delaunay, C. Salanoubat, S. Visanica, A. Stamatoullas, F. Isnard, A. Marfaing-Koka, S. de Botton, Y. Chelghoum, A.-L. Taksin, I. Plantier, S. Ame, S. Boehrer, C. Gardin, C. L. Beach, L. Ades, P. Fenaux, Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine, Blood, 2010, 117, 2, 403

    CrossRef

  11. 11
    M Y Follo, C Finelli, S Mongiorgi, C Clissa, F Chiarini, G Ramazzotti, S Paolini, G Martinelli, A M Martelli, L Cocco, Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes, Leukemia, 2010, 25, 2, 271

    CrossRef

  12. 12
    Alfonso Quintás-Cardama, Fabio P. S. Santos, Guillermo Garcia-Manero, Therapy with azanucleosides for myelodysplastic syndromes, Nature Reviews Clinical Oncology, 2010, 7, 8, 433

    CrossRef

View Full Article (HTML) Get PDF (154K)